Completed PHASE1 INTERVENTIONAL 4-arm NCT01093742

A Study of HM10560A in Healthy Male Subject

A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM10560A After S.C. Administration in Healthy Male Subjects

Sponsor: Hanmi Pharmaceutical Company Limited

Conditions Healthy

Interventions HM10560A Placebo

Updated 6 times since 2017 Last updated: Feb 6, 2014 Started: Mar 31, 2010 Primary completion: Aug 31, 2010 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01093742, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Hanmi Pharmaceutical Company Limited, it has been updated 6 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hanmi Pharmaceutical Company Limited

Data source: Hanmi Pharmaceutical Company Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea